文献速递肝胆胰外科

二阶段肝切除结局的系统综述与荟萃分析:肝脏再生策略

Outcomes following 2-stage hepatectomy: Systematic review and meta-analysis exploring liver regeneration strategies.
PubMed 文献 · Surgery · 2026-05-08

该系统综述与荟萃分析纳入103项研究共5891例患者,评估二阶段肝切除中不同肝脏再生策略的结局。联合肝脏分隔和门静脉结扎的二阶段肝切除未来肝剩余体积增长68.5%、二阶段完成率95%,死亡率与其他策略无显著差异。

要点

  • 联合肝脏分隔和门静脉结扎的二阶段肝切除未来肝剩余体积增长68.5%,二阶段完成率95%。
  • 联合肝脏分隔和门静脉结扎的二阶段肝切除死亡率与其他策略无统计学显著差异。

核心结论

  • 肝静脉阻断联合门静脉栓塞较单独门静脉栓塞未来肝剩余体积增长更显著,但二阶段可行性未见明确优势。
  • 联合肝脏分隔和门静脉结扎的二阶段肝切除未来肝剩余体积增长和二阶段完成率最高,死亡率与其他策略无统计学显著差异。

研究设计与样本

  • 荟萃分析共纳入103项研究、5891例患者。
  • 主要结局为未来肝剩余体积增长,次要结局包括二阶段可行性、并发症和死亡率。

主要发现

  • 非比较性肝静脉阻断联合门静脉栓塞研究的未来肝剩余体积平均增长36.8%。
  • 肝静脉阻断联合门静脉栓塞后二阶段可行性为78%,与单独门静脉栓塞相似。
  • 联合肝脏分隔和门静脉结扎的二阶段肝切除未来肝剩余体积平均增长68.5%,二阶段可行性率95%。
  • 联合肝脏分隔和门静脉结扎的二阶段肝切除并发症和死亡率与门静脉栓塞及肝静脉阻断联合门静脉栓塞无显著差异。

临床怎么用

  • 对未来肝剩余体积不足需二阶段肝切除患者,可综合评估肝静脉阻断联合门静脉栓塞或联合肝脏分隔和门静脉结扎的二阶段肝切除以促进未来肝剩余体积增长。
  • 选择联合肝脏分隔和门静脉结扎的二阶段肝切除时需注意其未来肝剩余体积增长和二阶段完成率高,但需严格筛选患者。

局限性

  • 作者指出需谨慎选择患者并开展进一步前瞻性研究,以明确肝静脉阻断联合门静脉栓塞和联合肝脏分隔和门静脉结扎的二阶段肝切除在二阶段肝切除中的最佳角色。
  • 结论受所分析数据的局限性约束。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Insufficient future liver remnant volume remains a critical challenge in 2-stage hepatectomy. This meta-analysis aimed to evaluate the outcome in distinct 2-stage hepatectomies with a focus on hepatic vein occlusion combined with portal vein embolization and associating liver partition and portal vein ligation for staged hepatectomy. METHODS: A systematic literature search was conducted in MEDLINE (PubMed) up to December 2024. Comparative and noncomparative studies were included. The primary outcome was the observed increase in future liver remnant. Secondary outcomes included feasibility of stage 2, morbidity, and mortality. RESULTS: The meta-analysis included 103 studies (5,891 patients). Noncomparative hepatic vein occlusion combined with portal vein embolization studies showed a mean future liver remnant increase of 36.8%. Compared with portal vein embolization, hepatic vein occlusion combined with portal vein embolization resulted in a significantly greater future liver remnant increase (mean difference 24.5%, P < .01) despite a smaller initial future liver remnant volume. The feasibility of stage 2 was 78% after hepatic vein occlusion combined with portal vein embolization and similar to portal vein embolization alone. Associating liver partition and portal vein ligation for staged hepatectomy demonstrated a substantial mean future liver remnant increase (68.5%) and a high stage 2 feasibility rate (95%). Morbidity and mortality rates following associating liver partition and portal vein ligation for staged hepatectomy were not significantly different from those of portal vein embolization and hepatic vein occlusion combined with portal vein embolization. CONCLUSION: Hepatic vein occlusion combined with portal vein embolization was associated with a more pronounced hypertrophy response compared with portal vein embolization in terms of future liver remnant growth, although a clear advantage in second-stage feasibility was not observed. Within the limitations of the analyzed data, associating liver partition and portal vein ligation for staged hepatectomy was associated with the highest future liver remnant increase and completion rates, whereas mortality rates showed no statistically significant difference compared with other strategies. Careful patient selection and further prospective studies are warranted to define the optimal role of hepatic vein occlusion combined with portal vein embolization and associating liver partition and portal vein ligation for staged hepatectomy in 2-stage hepatectomy.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Lüthy M, Helg F, Lopez-Lopez V, et al. Outcomes following 2-stage hepatectomy: Systematic review and meta-analysis exploring liver regeneration strategies. Surgery. 2026. PMID: 42105697. doi:10.1016/j.surg.2026.110217

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。